業績一覧

原著論文

2022

  • 1. Shinji Kobuchi, Megumi Matsui, Yukako Ito: Predictive marker for exposure-driven haematological toxicity of tegafur-uracil and proposed modified-dosage regimen by pharmacometric approach in rats. Xenobiotica, 52(7), 697-706 (2022).
  • 2. Shinji Kobuchi, Motoi Tsuda, Maki Okamura, Takanori Nakamura, Yukako Ito: Pharmacokinetic-pharmacodynamic model predicts uracil-tegafur effect on tumor shrinkage and myelosuppression in colorectal cancer rat model. Anticancer Res., in press.
  • 3. Shinji Kobuchi, Naoya Kanda, Taichi Okumi, Yuma Kano, Himawari Tachi, Yukako Ito, and Toshiyuki Sakaeda: Comparing the pharmacokinetics and organ/tissue distribution of anti-methicillin-resistant Staphylococcus aureus agents using a rat model of sepsis. Xenobiotica, 52(6), 583-590 (2022).
  • 4. Tetsuo Hayakawa, Ken-Ichiro Kato, Shinji Kobuchi, Kaede Kataoka, Toshiyuki Sakaeda: Associations of plasma concentration profiles of dapagliflozin, a selective inhibitor of sodium–glucose co-transporter type 2, with its effects in Japanese patients with type 2 diabetes mellitus. Pharmaceuticals 15(2), 203 (2022).
ページ上部へ

2021

  • 1. Shinji Kobuchi, Yusuke Kita, Yukiko Hiramatsu, Kenji Sasaki, Tomoya Uno, Yukako Ito, and Toshiyuki Sakaeda. Comparison of in vivo transportability of anti-methicillin-resistant staphylococcus aureus (MRSA) agents into intracellular and extracellular tissue spaces in rats. J. Pharm. Sci., 110(2), 898-904 (2021).
  • 2. Shuhei Sakai, Shinji Kobuchi, Yukako Ito, Toshiyuki Sakaeda. A physiologically based pharmacokinetic-pharmacodynamic model for capecitabine in colorectal cancer rats: simulation of antitumor efficacy at various administration schedules. Eur. J. Drug Metab. Pharmacokinet., 46, 301-315 (2021).
  • 3. Daisuke Taniguchi, Hironosuke Watanabe, Yoshitomo Morinaga, Daisuke Sasaki, Junichi Matsuda, Shuntaro Sato, Norihito Kaku, Takuro Miyazaki, Keitaro Matsumoto, Tomoshi Tsuchiya, Toshiyuki Sakaeda, Katsunori Yanagihara, Takeshi Nagayasu. Safety, efficacy, and analysis of key parameters after prophylactic administration of a sustained-release formulation of azithromycin in lung cancer surgery. Ann Palliat Med., 10(5), 5098-5107 (2021)
  • 4. Shinji Kobuchi, Miyu Kai, Yukako Ito. Population pharmacokinetic model-based evaluation of intact oxaliplatin in rats with acute kidney injury. Cancers 13(24), 6382 (2021).
ページ上部へ

2020

  • 1. Yukako Ito, Shinji Kobuchi, Mako Takesada, Miki Morimoto. Effect of intact oxaliplatin in plasma on a cold allodynia after multiple administrations in colorectal cancer model rats. Ann Palliat Med.,apm-20-542 (2020).
  • 2. Yukako Ito, Eriko Inoue, Yuki Matsui, Shinji Kobuch, Chiami Moyama, Kikuko Amagase, Mayumi Yoshimura, Yuzuru Ikehara, Susumu Nakata, and Hayao Nakanishi. Cytology-based detection of circulating tumour cells in human pancreatic cancer xenograft models with KRAS mutation. Anticancer Res., 40(12), 6781-6789 (2020).
  • 3. Shinji Kobuchi, Atsushi Shigemura, Yukako Ito, and Toshiyuki Sakaeda: A validated LC–MS/MS method for the low-level determination of pemafibrate, a novel SPPARMα, in plasma. Bioanalysis, 12(10), 683-692 (2020).
  • 4. Shinji Kobuchi, Teruhiko Kabata, Koki Maeda, Yukako Ito, Toshiyuki Sakaeda: Pharmacokinetics of Macrolide Antibiotics and Transport into the Interstitial Fluid: Comparison among Erythromycin, Clarithromycin, and Azithromycin. Antibiotics, 9(4), 199 (2020).
  • 5. Shinji Kobuchi, Eisuke Matsumura, Yukako Ito, Toshiyuki Sakaeda: Population pharmacokinetic model-based evaluation of circadian variations in plasma 5-fluorouracil concentrations during long-term infusion in rats: a comparison with oral anticancer prodrugs. J. Pharm. Sci., 109(7), 2356-2361 (2020).
  • 6. Shuhei Sakai, Shinji Kobuchi, Yukako Ito, Toshiyuki Sakaeda: Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model. Cancer Chemother. Pharmacol., 85(5): 869-880 (2020).
  • 7. Shinji Kobuchi, Risa Shimizu, Yukako Ito: Semi-Mechanism-based Pharmacokinetic-Toxicodynamic Model of Oxaliplatin-induced Acute and Chronic Neuropathy. Pharmaceutics, 12(2), 125 (2020).
  • 8. Shinji Kobuchi, Akihiro Fujita, Akihito Kato, Hiromu Kobayashi, Yukako Ito, and Toshiyuki Sakaeda: Pharmacokinetics and lung distribution of macrolide antibiotics in sepsis model rats. Xenobiotica, 50(5), 552-558 (2020).
  • 9. Shinji Kobuchi, Yosuke Katsuyama, Yukako Ito: Mechanism-based pharmacokinetic– pharmacodynamic (PK-PD) modeling and simulation of oxaliplatin for hematological toxicity in rats. Xenobiotica, 50(2), 146-153, (2020).
ページ上部へ

2019

  • 1. Yukako Ito, Shinji Kobuchi, Waki Takesada, Chiharu Takahashi. Assessment of oxaliplatin-induced chronic neuropathy and anticancer efficacy through pharmacokinetic and toxicodynamic evaluation of a rat model of colorectal cancer. Anticancer Res. 39(8), 4207-4213 (2019).
  • 2. Shinji Kobuchi, Mako Akutagawa, Yukako Ito, and Toshiyuki Sakaeda. Association between the pharmacokinetics of capecitabine and the plasma dihydrouracil to uracil ratio in rat: a surrogate biomarker for dihydropyrimidine dehydrogenase activity. Biopharm. Drug Dispos. 40(1), 44-48 (2019).
  • 3. Akiko Kuwahara*, Shinji Kobuchi*, Takao Tamura. Association between circadian and chemotherapeutic cycle effects on plasma concentration of 5-fluorouracil and the clinical outcome following definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in patients with esophageal squamous cell carcinoma. Oncol. Lett. 17(1), 668-675 (2019). * Contributed equally
  • 4. Yutaka Takaoka, Atsuko Takeuchi, Aki Sugano, Kenji Miura, Mika Ohta, Takashi Suzuki, Daisuke Kobayashi, Takuji Kimura, Juichi Sato, Nobutaro Ban, Hisahide Nishio, Toshiyuki Sakaeda. Establishment of the experimental procedure for prediction of conjugation capacity in mutant UGT1A1. PLoS One 14(11), e0225244 (2019).
  • 5. Keiko Nakao, Shinji Kobuchi, Shuhei Marutani, Ayano Iwazaki, Akihiro Tamiya, Shunichi Isa, Kyoichi Okishio, Masaki Kanazu, Motohiro Tamiya, Tomonori Hirashima, Kimie Imai, Toshiyuki Sakaeda, and Shinji Atagi. Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. Sci. Rep. 9(1), 18202 (2019).
ページ上部へ

2018

  • 1. Yukako Ito, Shinji Kobuchi, Risa Shimizu, Yosuke Katsuyama: Pharmacokinetic and toxicodynamic evaluation of oxaliplatin-induced neuropathy and hematological toxicity in rats. Cancer Chemother. Pharmacol., 81, 155-161 (2018).
  • 2. Shinji Kobuchi, Yukiko Yazaki, Yukako Ito, and Toshiyuki Sakaeda: Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats. Eur. J. Pharm. Sci., 112, 152-158 (2018).
  • 3. Mika Ohta, Aki Sugano, Naoya Hatano, Hirotaka Sato, Hirofumi Shimada, Hitoshi Niwa, Toshiyuki Sakaeda, Hajime Tei, Yoshiyuki Sakaki, Ken-ichi Yamamura, Yutaka Takaoka: Co-precipitation molecules hemopexin and transferrin may be key molecules for fibrillogenesis in TTR V30M amyloidogenesis. Transgenic. Res., 27, 15-23 (2018).
  • 4. Toshiyuki Sakaeda, Shinji Kobuchi, Ryosuke Yoshioka, Mariko Haruna, Noriko Takahata, Yukako Ito, Aki Sugano, Kazuki Fukuzawa, Toshiki Hayase, Taro Hayakawa, Hideo Nakayama, Yutaka Takaoka and Masahiro Tohkin: Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int. J. Med. Sci., 15(9), 937-943 (2018).
  • 5. Shinji Kobuchi, Yukako Ito, Takamatsu Daiki, and Toshiyuki Sakaeda: Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats. Eur. J. Pharm. Sci., 123, 452-458 (2018).
ページ上部へ

2017

  • 1. Yukako Ito, Shinji Kobuchi, Risa Shimizu, Yosuke Katsuyama: Pharmacokinetic and toxicodynamic evaluation of oxaliplatin-induced neuropathy and hematological toxicity in rats. Cancer Chemother. Pharmacol., (in press).
  • 2. Yukako Ito, Shinji Kobuchi, Genta Inoue, Eisaku Kakumu, Miki Aoki, Toshiyuki Sakaeda, Kanji Takada: Dissolving microneedles for enhanced local delivery of capsaicin to rat skin tissue. J. Drug Target., 25(5), 420-424 (2017).
  • 3. Shinji Kobuchi, Yukako Ito, Toshiyuki Sakaeda: Population pharmacokinetic-pharmacodynamic modeling of 5-fluorouracil for toxicities in rats. Eur. J. Drug Metab. Pharmacokinet., 42, 707-718 (2017).
  • 4. Shinji Kobuchi, Megumi Matsuno, Momoko Kawamoto, Naoto Kojima, Yukako Ito, Masayuki Yamashita, Toshiyuki Sakaeda:　A simple and rapid LC-MS/MS method for quantitation of luseogliflozin in rat plasma and its application to a PK study. Bioanalysis, 9(2), 163-171 (2017).
  • 5. Yukako Ito, Kengo Matsumoto, Noriyuki Osakama, Ryosuke Yoshioka, Shinji Kobuchi, Toshiyuki Sakaeda, Kanji Takada: Dissolving microneedles as skin allergy test device. Biol. Pharm. Bull., 40, 531–534 (2017).
  • 6. Kazutaka Aonuma, Tsuyoshi Shiga, Hirotsugu Atarashi, Kosuke Doki, Hirotoshi Echizen, Nobuhisa Hagiwara, Junichi Hasegawa, Hideharu Hayashi, Kenzo Hirao, Fukiko Ichida, Takanori Ikeda, Yorinobu Maeda, Naoki Matsumoto, Toshiyuki Sakaeda, Wataru Shimizu, Mitsuru Sugawara, Kyoichi Totsuka, Yoshimasa Tsuchishita, Kazuyuki Ueno, Eiichi Watanabe, Masayuki Hashiguchi, Sumio Hirata, Hidefumi Kasai, Yoshiaki Matsumoto, Akihiko Nogami, Yukio Sekiguchi, Tokuko Shinohara, Atsushi Sugiyama, Naokata Sumitomo, Atsushi Suzuki, Naohiko Takahashi, Eiji Yukawa, Masato Homma, Minoru Horie, Hiroshi Inoue, Hiroshi Ito, Takanori Miura, Tohru Ohe, Kimikazu Shinozaki, Kazuhiko Tanaka, on behalf of the Japanese Circulation Society and the Japanese Society of Therapeutic Drug Monitoring Joint Working Group: Guidelines for therapeutic drug monitoring of cardiovascular drugs clinical use of blood drug concentration monitoring (JCS 2015) -digest version-. Circ. J., 81, 581-612 (2017).
  • 7. Lixia Qiang, Yanxia Guan, Xiangshun Li, Li Liu, Yanshuang Mu, Aki Sugano, Yutaka Takaoka, Toshiyuki Sakaeda, Bruno P. Imbimbo, Ken-Ichi Yamamura, Shoude Jin, Zhenghua Li: CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects. Amyloid, 24(1), 42-51 (2017).
  • 8. 尾濵直子、三浦誠、友沢明徳、黄前尚樹、松岡加世子、桒原晶子、山森元博、角山香織、栄田敏之: 高齢者における脂肪乳剤投与による問題点の抽出と適切な対処法への寄与を目指した多施設共同研究. 日本病院薬剤師会雑誌, 53(8), 993-997 (2017).
  • 9. 河渕真治、藤田章洋、伊藤由佳子、桒原晶子、中村任、安井裕之、相引眞幸、栄田敏之: 敗血症患者におけるアジスロマイシン持続投与後の体内動態および基礎的検討. TDM研究, 34(4), 119-125 (2017).
ページ上部へ

2016

  • 1. Yukako Ito, Yuto Inagaki, Shinji Kobuchi, Kanji Takada, and Toshiyuki Sakaeda: Therapeutic drug monitoring of vancomycin in dermal interstitial fluid using dissolving microneedles. Int. J. Med. Sci., 13(4), 271-276 (2016).
  • 2. Shinji Kobuchi, Yukako Ito, Yuya Nakano, and Toshiyuki Sakaeda: Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats. Xenobiotica, 46(7), 597-604 (2016).
  • 3. Shinji Kobuchi, Kyoka Yano, Yukako Ito, and Toshiyuki Sakaeda: A validated LC–MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. Biomed. Chromatogr., 30, 1549-1555 (2016).
  • 4. Shinji Kobuchi, Megumi Matsuno, Etsuko Fukuda, Yukako Ito, and Toshiyuki Sakaeda: Development and validation of an LC–MS/MS method for the determination of tofogliflozin in plasma and its application to a pharmacokinetic study in rats. J. Chromatogr. B, 1027, 227-233 (2016).
  • 5. Shinji Kobuchi, Asuka Hayashi, Mayu Taniguchi, Yukako Ito, Takao Tamura and Toshiyuki Sakaeda: Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil. Cancer Chemother. Pharmacol., 78, 517-523 (2016).
  • 6. Makoto Miura, Akiko Kuwahara, Akinori Tomozawa, Naoki Omae, Motohiro Yamamori, Kaori Kadoyama, and Toshiyuki Sakaeda: Lower body mass index is a risk factor for in-hospital mortality of elderly Japanese patients treated with ampicillin/sulbactam. Int. J. Med. Sci., 13(10), 749-753 (2016).
  • 7. Shinji Kobuchi, Miki Aoki, Chiaki Inoue, Hiroyuki Murakami, Akiko Kuwahara, Tsutomu Nakamura, Hiroyuki Yasui, Yukako Ito, Kanji Takada, and Toshiyuki Sakaeda: Transport of azithromycin into extravascular space in rats. Antimicrob. Agents Chemother., 60(11), 6823-6827 (2016).
ページ上部へ

2015

  • 1. Shinji Kobuchi, Yukako Ito, Kyoka Yano, and Toshiyuki Sakaeda: A quantitative LC-MS/MS method for determination of ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats. J. Chromatogr. B, 1000, 22-28 (2015).
  • 2. Shinji Kobuchi, Yukako Ito, Taro Hayakawa, Asako Nishimura, Nobuhito Shibata, Kanji Takada, and Toshiyuki Sakaeda: Semi-physiological pharmacokinetic–pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats. Xenobiotica, 45(1), 19-28 (2015).
  • 3. Goji Kimura, Kaori Kadoyama, J.B. Brown, Tsutomu Nakamura, Ikuya Miki, Kohshi Nisiguchi, Toshiyuki Sakaeda, Yasushi Okuno: Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database. Int J Med Sci, 12(2), 135-140 (2015).
ページ上部へ

2014

  • 1. Yukako Ito, Shinji Kobuchi, Yutaro Takemura, Miki Aoki, Marina Haruna, Toshiyuki Sakaeda, Kanji Takada: Prolonged hypoglycemic effects obtained by two-layered dissolving microneedles containing insulin glargine. J. Drug Del. Sci. Tech., 24, 601-606 (2014).
  • 2. Yukako Ito, Mayu Taniguchi, Asuka Hayashi, Miku Anai, Shinya Morita, Emi Ko, Naoko Yoshimoto, Yasuhiro Yoshi, Shinji Kobuchi, Toshiyuki Sakaeda, Kanji Takada: Application of dissolving microneedles to glucose monitoring through dermal interstitial fluid. Biol. Pharm. Bull., 37, 1776-1781 (2014).
  • 3. Shinji Kobuchi, Yukako Ito, Taro Hayakawa, Asako Nishimura, Nobuhito Shibata, Kanji Takada, and Toshiyuki Sakaeda: Pharmacokinetic–pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats. J. Pharmacol. Toxicol. Methods, 70, 134-144 (2014).
  • 4. Shinji Kobuchi, Yukako Ito, Taro Hayakawa, Shota Kuwano, Akiko Baba, Kota Shinohara, Asako Nishimura, Nobuhito Shibata, and Kanji Takada: Semi-physiological pharmacokinetic–pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil, and lymphocyte counts in rats. Xenobiotica, 44, 804-818 (2014).
  • 5. Tetsuya Minegaki, Akiko Kuwahara, Motohiro Yamamori, Tsutomu Nakamura, Tatsuya Okuno, Ikuya Miki, Hideaki Omatsu, Takao Tamura, Midori Hirai, Takeshi Azuma, Toshiyuki Sakaeda, Kohshi Nishiguchi. Genetic Polymorphisms in SLC23A2 as Predictive Biomarkers of Severe Acute Toxicities after Treatment with a Definitive 5-Fluorouracil/Cisplatin-Based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma. Int. J. Med. Sci., 11, 321-326 (2014).
  • 6. Toshiyuki Sakaeda, Kaori Kadoyama, Keiko Minami, Yasushi Okuno: Commonality of Drug-associated Adverse Events Detected by 4 Commonly Used Data Mining Algorithms. Int. J. Med. Sci., 11, 461-465 (2014).
  • 7. Kyoko Seki, Yasuo Tsuduki, Takeshi Ioroi, Michiko Yamane, Hiroko Yamauchi, Yukinari Shiraishi, Tadaaki Ogawa, Izumi Nakata, Kohshi Nishiguchi, Teruhisa Matsubayashi, Yoshihide Takakubo, Motohiro Yamamori, Akiko Kuwahara, Noboru Okamura, Toshiyuki Sakaeda: Serum Lactate Dehydrogenase Levels as a Predictive Marker of Oxaliplatin-Induced Hypersensitivity Reactions in Japanese Patients with Advanced Colorectal Cancer. Int. J. Med. Sci., 11, 641-645 (2014).
English